Hopkins S, Coleman C, Kelleher M, Keating S, Clarke S, O'Connell B, Mulcahy F, Bergin C
Dept of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin.
Ir Med J. 2005 Jul-Aug;98(7):208-9.
Neisseria gonorrhoeae cases are increasing in Ireland. Ciprofloxacin is often used as first line treatment for this infection in STI clinics. A retrospective study to analyze resistance in two Dublin clinics was undertaken. Cases were defined as patients from whom an isolate of N. gonorrhoea was recovered. All cases from two clinics between January 1997 and June 2003 were included. Antimicrobial resistance data was correlated with sex and sexuality. One thousand one hundred and eighty laboratory-confirmed cases were identified. Eighty seven percent were male. Sixty nine percent were MSM. Twenty seven percent of isolates demonstrated reduced susceptibility to penicillin and 6% to ciprofloxacin. Isolates with reduced susceptibility to ciprofloxacin increased year on year from 3.8% in 1997 to 15% in 2003. Prevalence of isolates of N. gonorrhoea with reduced susceptibility to ciprofloxacin has exceeded 10% in these clinics since 2002. In concordance with international guidelines, ceftriaxone became the treatment of choice for gonorrhoea in July 2003.
爱尔兰淋病奈瑟菌病例数正在增加。在性传播感染诊所，环丙沙星常被用作这种感染的一线治疗药物。开展了一项回顾性研究，以分析都柏林两家诊所的耐药情况。病例定义为分离出淋病奈瑟菌的患者。纳入了1997年1月至2003年6月期间两家诊所的所有病例。抗菌药物耐药数据与性别和性取向相关。共识别出1180例实验室确诊病例。其中87%为男性。69%为男男性行为者。27%的分离株对青霉素敏感性降低，6%对环丙沙星敏感性降低。对环丙沙星敏感性降低的分离株逐年增加，从1997年的3.8%增至2003年的15%。自2002年以来，这些诊所中对环丙沙星敏感性降低的淋病奈瑟菌分离株患病率已超过10%。根据国际指南，头孢曲松在2003年7月成为淋病的首选治疗药物。
